読み込み中
Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The company's preclinical portfolio is extensive, featuring VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, and VY-FXN01 for Friedreich's ataxia. Additionally, Voyager is pursuing a Tau program aimed at various tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, alongside initiatives for spinal muscular atrophy. To advance its gene therapy product pipeline, the company has forged strategic collaboration and licensing agreements with key industry players such as Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. These partnerships cover the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and maintains its corporate headquarters in Cambridge, Massachusetts.
前日終値
$2.45
+$0.08 · +3.38%
時間外
$2.49
+$0.04 · +1.63%
10月9日 19:30 ET
日中の時刻はETです。市場データは遅延する場合があります。
Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The company's preclinical portfolio is extensive, featuring VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, and VY-FXN01 for Friedreich's ataxia. Additionally, Voyager is pursuing a Tau program aimed at various tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, alongside initiatives for spinal muscular atrophy. To advance its gene therapy product pipeline, the company has forged strategic collaboration and licensing agreements with key industry players such as Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. These partnerships cover the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and maintains its corporate headquarters in Cambridge, Massachusetts.
日中レンジ
現在 $2.45
52週レンジ
現在 $2.45
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
47
適正価値
センチメント
44
まちまち
リスク
62
高リスク
モメンタム
34
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The company's preclinical portfolio is extensive, featuring VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, and VY-FXN01 for Friedreich's ataxia. Additionally, Voyager is pursuing a Tau program aimed at various tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, alongside initiatives for spinal muscular atrophy. To advance its gene therapy product pipeline, the company has forged strategic collaboration and licensing agreements with key industry players such as Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. These partnerships cover the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and maintains its corporate headquarters in Cambridge, Massachusetts.
日中レンジ
現在 $2.45
52週レンジ
現在 $2.45
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 4037.4万 USD | 8000.1万 USD | 2.5億 USD | 4090.7万 USD | 3741.5万 USD |
| 売上原価 | 1.32億 USD | — | 9217.2万 USD | 5576.4万 USD | 7378.7万 USD |
| 粗利益 | −9190万 USD | 8000.1万 USD | 1.58億 USD | −1485.7万 USD | −3637.2万 USD |
| 研究開発 | 1.35億 USD | 1.27億 USD | 9217.2万 USD | 6076.4万 USD | 7378.7万 USD |
| 販売・一般管理 | 3644.4万 USD | 3592万 USD | 3582.2万 USD | 3098万 USD | 3724.6万 USD |
| 営業費用 | 3994.4万 USD | 1.63億 USD | 3582.2万 USD | 3598万 USD | 3724.6万 USD |
| 受取利息 | 1061.8万 USD | 1832.8万 USD | 1172.1万 USD | 179.2万 USD | — |
| 減価償却費と償却費 | 406万 USD | 473.1万 USD | 444.1万 USD | 619.1万 USD | 516.5万 USD |
| 営業利益 | −1.32億 USD | −8328.7万 USD | 1.22億 USD | −5083.7万 USD | −7361.8万 USD |
| 純利益 | −1.2億 USD | −6500.2万 USD | 1.32億 USD | −4640.8万 USD | −7119.7万 USD |
会社概要が更新されました 2026年10月10日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$14.40
上昇余地（487.76%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI576.8万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM333.26万0.00%782.66億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF211.53万0.00%954億 USD0.05%$235+0.80%
Vanguard Russell 2000 ETFVTWO104.38万0.01%180億 USD0.06%$112.66+0.50%
iShares Biotechnology ETFIBB90.59万0.01%102.79億 USD0.44%$206.49+3.00%
Dimensional - US Small Cap ETFDFAS69.56万0.00%338.69億 USD0.31%$78.35+0.32%
Fidelity Enhanced Small Cap ETFFESM39.54万0.01%64.1億 USD0.28%$45.46+0.46%
iShares Micro-Cap ETFIWC39.01万0.03%13.17億 USD0.60%$183+0.11%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Biotechnology ETFIBBDimensional - US Small Cap ETFDFASFidelity Enhanced Small Cap ETFFESMiShares Micro-Cap ETFIWCAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
